Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases

American Journal of Hematology
V LévyR Zittoun

Abstract

Peripheral cytopenias are common in patients with agnogenic myeloid metaplasia (AMM). They are an important cause of morbidity and mortality, and their treatment is difficult. We report on 4 patients with AMM and severe cytopenia treated with danazol (400-600 mg/ day). Three of them became independent of red blood cell (RBC) transfusion, while the other had a slight reduction in RBC requirement. In addition, correction of thrombocytopenia and disappearance of splenomegaly were observed in 1 and 2 patients, respectively. No side effects were observed. In our experience, danazol appears effective and safe in the subset of patients with AMM whose disease is mainly characterized by bone-marrow failure. These data warrant further studies to evaluate this treatment and explore its mechanism of action.

References

Apr 1, 1991·British Journal of Haematology·E A StadtmauerD B Cines
Feb 26, 1987·The New England Journal of Medicine·A D SchreiberD B Cines
Mar 1, 1985·Annals of Internal Medicine·Y S AhnL M Pall
Jun 9, 1983·The New England Journal of Medicine·Y S AhnA G So
May 1, 1994·British Journal of Haematology·E WattelP Fenaux
Mar 1, 1994·British Journal of Haematology·K P DallaR K Shadduck
Sep 1, 1993·British Journal of Haematology·L CatalanoB Rotoli

❮ Previous
Next ❯

Citations

Feb 13, 2001·European Journal of Haematology·A TefferiM G Chen
Jun 20, 2002·European Journal of Haematology·G DamajO Hermine
Apr 27, 2000·The New England Journal of Medicine·A Tefferi
Nov 8, 2001·Leukemia & Lymphoma·R A Mesa, A Tefferi
Feb 24, 2005·British Journal of Haematology·Francisco Cervantes
May 18, 2016·Expert Opinion on Drug Safety·J M O'SullivanC N Harrison
Jun 3, 2017·Expert Review of Hematology·Iram SaeedClaire N Harrison
Nov 15, 2002·International Journal of Hematology·Ruben A Mesa
Apr 29, 2010·Current Hematologic Malignancy Reports·Ruben A Mesa
Feb 16, 2006·Hematological Oncology·John T Reilly
Jun 2, 2012·British Journal of Haematology·John T ReillyUNKNOWN Writing group: British Committee for Standards in Haematology
Oct 2, 2012·Molecular Diagnosis & Therapy·Raoul TibesRuben A Mesa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.